Latest News and Press Releases

Tevas Biosimilar PONLIMSI™ ist nun von der FDA für alle Indikationen des Referenzprodukts Prolia® (Denosumab) zur Behandlung verschiedener schwerer Knochenerkrankungen zugelassen.Tevas vorgeschlagener...

Le médicament biosimilaire de Teva, PONLIMSI™, est désormais approuvé par la FDA pour toutes les indications du produit de référence, Prolia® (dénosumab), dans le cadre du traitement de diverses...

MediPharm Labs, today announced its financial results for the full year and three months ended December 31st, 2025.

With Priority Review designation, FDA set a Sept. 27 PDUFA date for approval decisionLirafugratinib achieved a 46.5% ORR, in CCA patients with FGFR2 fusion and rearrangement Fort Lee, N.J., March ...

Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...

- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically...

PHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development...

Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific clinical trial design and treatment approaches Manuscript...

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA...

Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s disease Additional data submitted to the U.S. FDA with the...

MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...

Appili Presentation Highlights Recent Collaborations and Funding Milestones Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities HALIFAX,...

Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June...

PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024

Reaffirms guidance to resubmit the Anaphylm NDA in Q3 2026Received clarifying feedback from the FDA on pharmacokinetic (PK) and human factor (HF) study designsFinal FDA meeting minutes expected by...

Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs Conference Call and Webcast Today at 8:00 am Eastern Time ...

– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV1 with many patients experiencing...

Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 ...

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The PD-1 resistant head and neck...

- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – - Current data package...

U.S. FDA Fast Track designation granted to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα), for the treatment of patients with advanced or metastatic platinum-resistant ovarian...

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Carcinoid Tumor Market Report 2026" has been added to ResearchAndMarkets.com's offering.The global carcinoid tumor market is rapidly expanding, with...

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Cutaneous Squamous Cell Carcinoma (cSCC) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The cutaneous squamous cell...

Global Cling Films Market is projected to grow from US$ 6,426.11 million in 2024 to US$ 9,226.30 million by 2031, registering a CAGR of 5.4%

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Pancreatic Adenocarcinoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The pancreatic adenocarcinoma...

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Paraganglioma Market Report 2026" has been added to ResearchAndMarkets.com's offering.The paraganglioma market is on an upward trajectory, with...

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers...

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Uveal Neoplasms Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global uveal neoplasms market has demonstrated...

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Non-Muscle Invasive Bladder Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The non-muscle invasive bladder...

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Non-Small Cell Lung Cancer (NSCLC) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The non-small cell lung cancer...

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Oncology Devices Market Report 2026" has been added to ResearchAndMarkets.com's offering.The oncology devices market has witnessed significant...

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Cancer Clinical Decision Tools Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global cancer clinical decision tools...

Ad hoc announcement pursuant to Art. 53 LR Phase 2 results show a statistically significant dose-dependent response on total sleep time with clinically meaningful improvements across multiple sleep...

NEW YORK, March 29, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between...

Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta...

NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra...

NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025...

Gelatin trick 2026 warning: does the viral gelatin trick recipe work? Pink gelatin trick, ice gelatin trick, and Gelatine Sculpt examined.

2026 SteelPower performance report covers male enhancement formula details, ingredient research context, pricing, and guarantee disclosures.

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in...

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving...

Gelatide Drops under investigation: 2026 consumer report on Gelatide-1 claims, fake gelatin trick recipe, ingredient research, and refund terms.

SonusZen hearing support ingredients, Sonus Zen tinnitus supplement formulation transparency, B vitamin research, auditory health claims for 2026

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at 2026 AAD

NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Atara...

TheraWolf PainBalm and NeuroBalm claims evaluated: ingredient disclosures, topical relief expectations, pricing, and what buyers overlook in 2026

BareEarth releases 2026 overview of its grounding bed sheets earthing claims, silver-fiber conductivity, safety considerations, and pricing.

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.

Herpafend ingredient safety, drug interactions, and supplement claim context addressed for HSV wellness consumers considering purchase in 2026

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Disc...